Literature DB >> 31469748

Perioperative Probiotics or Synbiotics in Adults Undergoing Elective Abdominal Surgery: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Abeed H Chowdhury1, Alfred Adiamah1, Anisa Kushairi1, Krishna K Varadhan1, Zeljko Krznaric2, Anil D Kulkarni3, Keith R Neal4, Dileep N Lobo1,5.   

Abstract

OBJECTIVE: To define the impact of perioperative treatment with probiotics or synbiotics on postoperative outcome in patients undergoing abdominal surgery.
BACKGROUND: Postoperative surgical infection accounts for a third of all cases of sepsis, and is a leading cause of morbidity and mortality. Probiotics, prebiotics, and synbiotics (preparations that combine probiotics and prebiotics) are nutritional adjuncts that are emerging as novel therapeutic modalities for preventing surgical infections. However, current evidence on their effects is conflicting.
METHODS: A comprehensive search of the PubMed, Embase, and WHO Global Index Medicus electronic databases was performed to identify randomized controlled trials evaluating probiotics or synbiotics in adult patients undergoing elective colorectal, upper gastrointestinal, transplant, or hepatopancreaticobiliary surgery. Bibliographies of studies were also searched. The primary outcome measure was incidence of postoperative infectious complications. Secondary outcomes included incidence of noninfectious complications, mortality, length of hospital stay, and any treatment-related adverse events. Quantitative pooling of the data was undertaken using a random effects model.
RESULTS: A total of 34 randomized controlled trials reporting on 2723 participants were included. In the intervention arm, 1354 patients received prebiotic or symbiotic preparations, whereas 1369 patients in the control arm received placebo or standard care. Perioperative administration of either probiotics or synbiotics significantly reduced the risk of infectious complications following abdominal surgery [relative risk (RR) 0.56; 95% confidence interval (CI) 0.46-0.69; P < 0.00001, n = 2723, I = 42%]. Synbiotics showed greater effect on postoperative infections compared with probiotics alone (synbiotics RR: 0.46; 95% CI: 0.33-0.66; P < 0.0001, n = 1399, I = 53% probiotics RR: 0.65; 95% CI: 0.53-0.80; P < 0.0001, n = 1324, I = 18%). Synbiotics but not probiotics also led to a reduction in total length of stay (synbiotics weighted mean difference: -3.89; 95% CI: -6.60 to -1.18 days; P = 0.005, n = 535, I = 91% probiotics RR: -0.65; 95% CI: -2.03-0.72; P = 0.35, n = 294, I = 65%). There were no significant differences in mortality (RR: 0.98; 95% CI: 0.54-1.80; P = 0.96, n = 1729, I = 0%) or noninfectious complications between the intervention and control groups. The preparations were well tolerated with no significant adverse events reported.
CONCLUSIONS: Probiotics and synbiotics are safe and effective nutritional adjuncts in reducing postoperative infective complications in elective abdominal surgery. The treatment effects are greatest with synbiotics.

Entities:  

Mesh:

Year:  2020        PMID: 31469748     DOI: 10.1097/SLA.0000000000003581

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  15 in total

1.  Defining Microbiome Readiness for Surgery: Dietary Prehabilitation and Stool Biomarkers as Predictive Tools to Improve Outcome.

Authors:  Robert Keskey; Emily Papazian; Adam Lam; Tiffany Toni; Sanjiv Hyoju; Renee Thewissen; Alexander Zaborin; Olga Zaborina; John C Alverdy
Journal:  Ann Surg       Date:  2020-11-04       Impact factor: 13.787

2.  Probiotic supplementation in neonates with congenital gastrointestinal surgical conditions: a pilot randomised controlled trial.

Authors:  Shripada Rao; Meera Esvaran; Liwei Chen; Anthony D Keil; Ian Gollow; Karen Simmer; Bernd Wemheuer; Patricia Conway; Sanjay Patole
Journal:  Pediatr Res       Date:  2022-01-03       Impact factor: 3.953

Review 3.  Engineering the Microbiome to Prevent Adverse Events: Challenges and Opportunities.

Authors:  Saad Khan; Ruth Hauptman; Libusha Kelly
Journal:  Annu Rev Pharmacol Toxicol       Date:  2020-10-13       Impact factor: 16.459

4.  Effect of Probiotics on Oral Candidiasis: A Systematic Review and Meta-Analysis.

Authors:  Tiziana Mundula; Federica Ricci; Beatrice Barbetta; Michela Baccini; Amedeo Amedei
Journal:  Nutrients       Date:  2019-10-14       Impact factor: 5.717

5.  Effects of both Pro- and Synbiotics in Liver Surgery and Transplantation with Special Focus on the Gut-Liver Axis-A Systematic Review and Meta-Analysis.

Authors:  Judith Kahn; Gudrun Pregartner; Peter Schemmer
Journal:  Nutrients       Date:  2020-08-15       Impact factor: 5.717

Review 6.  Radiotherapy and the gut microbiome: facts and fiction.

Authors:  Jing Liu; Chao Liu; Jinbo Yue
Journal:  Radiat Oncol       Date:  2021-01-13       Impact factor: 3.481

Review 7.  Gestational Diabetes, Colorectal Cancer, Bariatric Surgery, and Weight Loss among Diabetes Mellitus Patients: A Mini Review of the Interplay of Multispecies Probiotics.

Authors:  Emmanouil Benioudakis; Eleni Karlafti; Alexandra Bekiaridou; Triantafyllos Didangelos; Theodossis S Papavramidis
Journal:  Nutrients       Date:  2021-12-31       Impact factor: 5.717

Review 8.  Prospects and Challenges of the Study of Anti-Glycan Antibodies and Microbiota for the Monitoring of Gastrointestinal Cancer.

Authors:  Eugeniy P Smorodin
Journal:  Int J Mol Sci       Date:  2021-10-27       Impact factor: 5.923

9.  Prophylactic effects of probiotics or synbiotics on postoperative ileus after gastrointestinal cancer surgery: A meta-analysis of randomized controlled trials.

Authors:  Gang Tang; Wang Huang; Jie Tao; Zhengqiang Wei
Journal:  PLoS One       Date:  2022-03-01       Impact factor: 3.240

Review 10.  Probiotics Evaluation in Oncological Surgery: A Systematic Review of 36 Randomized Controlled Trials Assessing 21 Diverse Formulations.

Authors:  Elise Cogo; Mohamed Elsayed; Vivian Liang; Kieran Cooley; Christilynn Guerin; Athanasios Psihogios; Peter Papadogianis
Journal:  Curr Oncol       Date:  2021-12-07       Impact factor: 3.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.